Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension
This initial Canadian clinical experience of LBN in diverse patient and physician populations reflected its use in a real-world context, and demonstrated a significant IOP-lowering effect with LBN across patient groups seen in routine practice. Patient and physician satisfaction scores were high and in notable agreement.
Authors
- Paul Harasymowycz (ORCID: https://orcid.org/0000-0003-2524-7811)
- David Yan (ORCID: https://orcid.org/0000-0003-2919-4796)
- Cindy Hutnik (ORCID: https://orcid.org/0000-0001-9084-292X)
Institutions
- Mount Sinai Hospital (CA)
- University of Toronto (CA)
- Hôpital Maisonneuve-Rosemont (CA)
- Institute of Ophthalmology (MX)
- St Joseph's Health Care (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1007/s40123-025-01132-z
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00